Evidence map›Paper›PMID 36036746›Full record

Trial reportEuropean heart journal2022

Empagliflozin in acute myocardial infarction: the EMMY trial.

Dirk von Lewinski, Ewald Kolesnik, Norbert J Tripolt, Peter N Pferschy, Martin Benedikt, Markus Wallner, Hannes Alber, Rudolf Berger, Michael Lichtenauer, Christoph H Saely and 15 more

Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European heart journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03087773. Cited by 145 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed, 12 pooled it
36.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03087773 phase3completed

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

Ran2017Enrolled476Registered outcomes6Posted comparisons0ConditionsAcute Myocardial InfarctionArmsempagliflozin 10 mg, Placebo Oral Tablet
PMID 37475009PMID 31901799PMID 37236318PMID 37407956PMID 37777743PMID 38287198other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

145 citing papers in PubMed, 12 syntheses or guidelines pooled it, 273 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

85 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 12 institutions in 3 countries.

Dirk von LewinskiDepartment of Internal Medicine, Division of Cardiology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.ORCID 0000-0001-9996-6128
Ewald KolesnikDepartment of Internal Medicine, Division of Cardiology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.
Norbert J TripoltDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.
Peter N PferschyDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.
Martin BenediktDepartment of Internal Medicine, Division of Cardiology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.
Markus WallnerDepartment of Internal Medicine, Division of Cardiology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.
Hannes AlberDepartment of Cardiology, Public Hospital Klagenfurt am Woerthersee, Klagenfurt am Woerthersee, Austria.
Rudolf BergerDepartment of Internal Medicine, Brothers of Saint John of God Eisenstadt, Eisenstadt, Austria.
Michael LichtenauerDepartment of Internal Medicine II, Division of Cardiology and Internal Intensive Care Medicine, Paracelsus Medical Private University Salzburg, Salzburg, Austria.
Christoph H SaelyVorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.
Deddo MoertlKarl Landsteiner University of Health Sciences, 3050 Krems, Austria.
Pia AuerspergKarl Landsteiner University of Health Sciences, 3050 Krems, Austria.
Christian ReiterDepartment of Cardiology and Intensive Care Medicine, Kepler University Hospital Linz, Linz, Austria.
Thomas RiederDepartment of Medicine, Kardinal Schwarzenberg Hospital Schwarzach, Schwarzach, Austria.
Jolanta M Siller-MatulaDepartment of Cardiology, Medical University of Vienna, Vienna, Austria.
Gloria M GagerDepartment of Cardiology, Medical University of Vienna, Vienna, Austria.
Matthias Hasun2nd Medical Department with Cardiology and Intensive Care Medicine, Hospital Landstrasse, Vienna, Austria.
Franz Weidinger2nd Medical Department with Cardiology and Intensive Care Medicine, Hospital Landstrasse, Vienna, Austria.
Thomas R PieberDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.
Peter M ZechnerDepartment of Cardiology and Intensive Care Medicine, Hospital Graz South West, West Location, Graz, Austria.
Markus HerrmannClinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
Andreas ZirlikDepartment of Internal Medicine, Division of Cardiology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.ORCID 0000-0001-6290-3297
Rury R HolmanRadcliffe Department of Medicine, University of Oxford, Oxford, UK.
Abderrahim OulhajDepartment of Epidemiology and Population Health, College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, UAE.
Harald SourijDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.ORCID 0000-0003-3510-9594
Medical University of Graz · ATAustrian Competence Centre of Food Safety · ATMedical University of Vienna · ATUniversity of Applied Sciences St Pölten · ATGraz University Hospital · ATHospital of the Brothers of St. John of God · ATKepler Universitätsklinikum · ATKhalifa University of Science and Technology · AEKlinikum Klagenfurt · ATParacelsus Medical University · ATUniversity of Oxford · GBVorarlberg Institute for Vascular Investigation and Treatment · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsSodium-glucose co-transporter 2 inhibition reduces the risk of hospitalization for heart failure and for death in patients with symptomatic heart failure. However, trials investigating the effects of this drug class in patients following acute myocardial infarction are lacking. METHODS AND

resultsIn this academic, multicentre, double-blind trial, patients (n = 476) with acute myocardial infarction accompanied by a large creatine kinase elevation (>800 IU/L) were randomly assigned to empagliflozin 10 mg or matching placebo once daily within 72 h of percutaneous coronary intervention. The primary outcome was the N-terminal pro-hormone of brain natriuretic peptide (NT-proBNP) change over 26 weeks. Secondary outcomes included changes in echocardiographic parameters. Baseline median (interquartile range) NT-proBNP was 1294 (757-2246) pg/mL. NT-proBNP reduction was significantly greater in the empagliflozin group, compared with placebo, being 15% lower [95% confidence interval (CI) -4.4% to -23.6%] after adjusting for baseline NT-proBNP, sex, and diabetes status (P = 0.026). Absolute left-ventricular ejection fraction improvement was significantly greater (1.5%, 95% CI 0.2-2.9%, P = 0.029), mean E/e' reduction was 6.8% (95% CI 1.3-11.3%, P = 0.015) greater, and left-ventricular end-systolic and end-diastolic volumes were lower by 7.5 mL (95% CI 3.4-11.5 mL, P = 0.0003) and 9.7 mL (95% CI 3.7-15.7 mL, P = 0.0015), respectively, in the empagliflozin group, compared with placebo. Seven patients were hospitalized for heart failure (three in the empagliflozin group). Other predefined serious adverse events were rare and did not differ significantly between groups.

conclusionIn patients with a recent myocardial infarction, empagliflozin was associated with a significantly greater NT-proBNP reduction over 26 weeks, accompanied by a significant improvement in echocardiographic functional and structural parameters. CLINICALTRIALS.GOV REGISTRATION: NCT03087773.

Indexed as

Heart FailureMyocardial InfarctionBenzhydryl CompoundsBiomarkersGlucosidesHumansNatriuretic Peptide, BrainPeptide FragmentsStroke VolumeVentricular Function, LeftBenzhydryl CompoundsBiomarkersempagliflozinGlucosidesNatriuretic Peptide, BrainPeptide FragmentsClinical trialEmpagliflozinHeart failureMyocardial infarctionNT-proBNPRandomised controlled trial

Identifiers

PMID36036746
PMCPMC9622301
OpenAlexW4293447102

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.